P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy

Loren C. Denlinger, David M. Manthei, Max A. Seibold, Kwangmi Ahn, Eugene Bleecker, Homer A. Boushey, William Calhoun, Mario Castro, Vernon M. Chinchili, John V. Fahy, Greg A. Hawkins, Nicolina Icitovic, Elliot Israel, Nizar N. Jarjour, Tonya King, Monica Kraft, Stephen C. Lazarus, Erik Lehman, Richard J. Martin, Deborah A. Meyers & 8 others Stephen P. Peters, Dagna Sheerar, Lei Shi, E. Rand Sutherland, Stanley J. Szefler, Michael E. Wechsler, Christine A. Sorkness, Robert F. Lemanske

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rationale: The function of the P2X7 nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied. Objectives: To evaluate the association between P2X7, asthma exacerbations, and incomplete symptomc ontrol in a more diverse population. Methods: A matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X7 pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently. Measurements and Main Results: A total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β2-agonists use (odds ratio, 2.7; 95% confidence interval, 1.2-6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1-9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV1 reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase. Conclusions: P2X7 pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume187
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Asthma
Adrenal Cortex Hormones
Therapeutics
Purinergic P2X7 Receptors
Confidence Intervals
Albuterol
Prednisone
African Americans
Single Nucleotide Polymorphism
Nucleotides
Alleles
Odds Ratio
Research
Population

Keywords

  • Asthma
  • Asthma Clinical Research Network
  • Corticosteroids
  • Exacerbation
  • P2X

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. / Denlinger, Loren C.; Manthei, David M.; Seibold, Max A.; Ahn, Kwangmi; Bleecker, Eugene; Boushey, Homer A.; Calhoun, William; Castro, Mario; Chinchili, Vernon M.; Fahy, John V.; Hawkins, Greg A.; Icitovic, Nicolina; Israel, Elliot; Jarjour, Nizar N.; King, Tonya; Kraft, Monica; Lazarus, Stephen C.; Lehman, Erik; Martin, Richard J.; Meyers, Deborah A.; Peters, Stephen P.; Sheerar, Dagna; Shi, Lei; Sutherland, E. Rand; Szefler, Stanley J.; Wechsler, Michael E.; Sorkness, Christine A.; Lemanske, Robert F.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 187, No. 1, 01.01.2013, p. 28-33.

Research output: Contribution to journalArticle

Denlinger, LC, Manthei, DM, Seibold, MA, Ahn, K, Bleecker, E, Boushey, HA, Calhoun, W, Castro, M, Chinchili, VM, Fahy, JV, Hawkins, GA, Icitovic, N, Israel, E, Jarjour, NN, King, T, Kraft, M, Lazarus, SC, Lehman, E, Martin, RJ, Meyers, DA, Peters, SP, Sheerar, D, Shi, L, Sutherland, ER, Szefler, SJ, Wechsler, ME, Sorkness, CA & Lemanske, RF 2013, 'P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy', American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 1, pp. 28-33. https://doi.org/10.1164/rccm.201204-0750OC
Denlinger, Loren C. ; Manthei, David M. ; Seibold, Max A. ; Ahn, Kwangmi ; Bleecker, Eugene ; Boushey, Homer A. ; Calhoun, William ; Castro, Mario ; Chinchili, Vernon M. ; Fahy, John V. ; Hawkins, Greg A. ; Icitovic, Nicolina ; Israel, Elliot ; Jarjour, Nizar N. ; King, Tonya ; Kraft, Monica ; Lazarus, Stephen C. ; Lehman, Erik ; Martin, Richard J. ; Meyers, Deborah A. ; Peters, Stephen P. ; Sheerar, Dagna ; Shi, Lei ; Sutherland, E. Rand ; Szefler, Stanley J. ; Wechsler, Michael E. ; Sorkness, Christine A. ; Lemanske, Robert F. / P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. In: American Journal of Respiratory and Critical Care Medicine. 2013 ; Vol. 187, No. 1. pp. 28-33.
@article{8fe494f161364acd96ae8bd76c6dcaea,
title = "P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy",
abstract = "Rationale: The function of the P2X7 nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied. Objectives: To evaluate the association between P2X7, asthma exacerbations, and incomplete symptomc ontrol in a more diverse population. Methods: A matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X7 pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently. Measurements and Main Results: A total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β2-agonists use (odds ratio, 2.7; 95{\%} confidence interval, 1.2-6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1-9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV1 reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase. Conclusions: P2X7 pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.",
keywords = "Asthma, Asthma Clinical Research Network, Corticosteroids, Exacerbation, P2X",
author = "Denlinger, {Loren C.} and Manthei, {David M.} and Seibold, {Max A.} and Kwangmi Ahn and Eugene Bleecker and Boushey, {Homer A.} and William Calhoun and Mario Castro and Chinchili, {Vernon M.} and Fahy, {John V.} and Hawkins, {Greg A.} and Nicolina Icitovic and Elliot Israel and Jarjour, {Nizar N.} and Tonya King and Monica Kraft and Lazarus, {Stephen C.} and Erik Lehman and Martin, {Richard J.} and Meyers, {Deborah A.} and Peters, {Stephen P.} and Dagna Sheerar and Lei Shi and Sutherland, {E. Rand} and Szefler, {Stanley J.} and Wechsler, {Michael E.} and Sorkness, {Christine A.} and Lemanske, {Robert F.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1164/rccm.201204-0750OC",
language = "English (US)",
volume = "187",
pages = "28--33",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy

AU - Denlinger, Loren C.

AU - Manthei, David M.

AU - Seibold, Max A.

AU - Ahn, Kwangmi

AU - Bleecker, Eugene

AU - Boushey, Homer A.

AU - Calhoun, William

AU - Castro, Mario

AU - Chinchili, Vernon M.

AU - Fahy, John V.

AU - Hawkins, Greg A.

AU - Icitovic, Nicolina

AU - Israel, Elliot

AU - Jarjour, Nizar N.

AU - King, Tonya

AU - Kraft, Monica

AU - Lazarus, Stephen C.

AU - Lehman, Erik

AU - Martin, Richard J.

AU - Meyers, Deborah A.

AU - Peters, Stephen P.

AU - Sheerar, Dagna

AU - Shi, Lei

AU - Sutherland, E. Rand

AU - Szefler, Stanley J.

AU - Wechsler, Michael E.

AU - Sorkness, Christine A.

AU - Lemanske, Robert F.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Rationale: The function of the P2X7 nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied. Objectives: To evaluate the association between P2X7, asthma exacerbations, and incomplete symptomc ontrol in a more diverse population. Methods: A matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X7 pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently. Measurements and Main Results: A total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β2-agonists use (odds ratio, 2.7; 95% confidence interval, 1.2-6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1-9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV1 reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase. Conclusions: P2X7 pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.

AB - Rationale: The function of the P2X7 nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied. Objectives: To evaluate the association between P2X7, asthma exacerbations, and incomplete symptomc ontrol in a more diverse population. Methods: A matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X7 pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently. Measurements and Main Results: A total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β2-agonists use (odds ratio, 2.7; 95% confidence interval, 1.2-6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1-9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV1 reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase. Conclusions: P2X7 pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.

KW - Asthma

KW - Asthma Clinical Research Network

KW - Corticosteroids

KW - Exacerbation

KW - P2X

UR - http://www.scopus.com/inward/record.url?scp=84872003277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872003277&partnerID=8YFLogxK

U2 - 10.1164/rccm.201204-0750OC

DO - 10.1164/rccm.201204-0750OC

M3 - Article

VL - 187

SP - 28

EP - 33

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -